the latest implantable continuous glucose monitoring (CGM) system for adults with diabetes that can last up to a year. The previous monitor, Eversense E3, could last up to six months without ...

Senseonics has revealed promising results for its Eversense technology, a long-term implantable continuous glucose monitoring (CGM) system. The PRECISE II trial looked at the safety and ...

Glucotrack (Nasdaq:GCTK) announced that it expects FDA investigational device exemption for its long-term CBGM later this ...

GlucoTrack is a medical technology company whose two-year implantable Continuous Blood Glucose Monitoring (CBGM) technology provides discreet, accurate, real-time glucose readings. The company's ...

In a world where diabetes management is evolving at a rapid pace, the spotlight shines on non-invasive glucose monitors that ...

We are working in conjunction with Dr. Jacob Segil of CU Boulder and Dr. Richard Weir of CU Anschutz on an implantable glucose fuel cell for medical uses. Our team is interested in developing ...

1 The researchers speculated that when combined with a smartphone application, the technology could help patients with diabetes continuously and noninvasively monitor their blood glucose levels. Many ...

Glucotrack, Inc. (NASDAQ: GCTK) is focused on the design, development, and commercialization of novel technologies for people with diabetes. The Company is currently developing a long-term implantable ...